Faricimab
Faricimab is a monoclonal antibody designed to treat eye disorders, specifically targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2). It works by blocking these proteins, which are involved in the development of abnormal blood vessels in the eyes.Faricimab is primarily indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).
The recommended dosage of faricimab depends on the condition being treated and the individual patient's response. Typically, the initial dosing schedule involves an intravitreal injection every 4 weeks for the first several doses, followed by an adjustment based on the patient's response. Consult a healthcare provider for specific dosage recommendations.
Faricimab should not be used in patients with known hypersensitivity to the drug or its components.
Caution is advised in patients with a history of intraocular inflammation, as well as those with active or suspected ocular infections. Patients should be monitored for increased intraocular pressure and signs of retinal detachment. Women who are pregnant, nursing, or planning to become pregnant should consult their healthcare provider before starting treatment.
Common side effects of faricimab may include conjunctival hemorrhage, eye pain, and increased intraocular pressure. Less common but serious side effects may include endophthalmitis, retinal detachment, and intraocular inflammation. Patients should report any sudden changes in vision to their healthcare provider.
There are no known significant drug interactions with faricimab. However, patients should inform their healthcare provider of all medications they are taking to avoid any potential interactions.
